R&D Partner Content 2nd ADC Payload Summit Diversifying ADC Payloads as Warheads for Overcoming Tumor Resistance, With Optimized Efficacy, Potency, Mechanisms & Differentiated IP
Oncology Antibody drug conjugates – The time is now The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs ca
Partner Content Partner Content BioPharmaLogic, Antikor Biopharma and UCL Host 2 Must Attend... ADC Summit
Partner Content Partner Content Exclusive Speaker Interview from Seattle Genetics for SMi’s ... Interview from Seattle Genetics
Partner Content Partner Content Hear the Keynote Addresses from MedImmune and Spirogen this ... Antibodies & Antibody Drug Conjugates
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.